Inventor · disambiguated record
Charles Akle
Also filed as: AKLE CHARLES
11 granted patents·4 pending applications·41 citations·filing 2012–2024
89Inventor score
Top patents by PatentIndex Score
15 records- 0193US11318193B2Immunogenic treatment of cancerIMMODULON THERAPEUTICS LTD·Filed 2018·Granted May 3, 2022·9 cites·12 claims
- 0291US11554166B2Immunogenic treatment of cancerIMMODULON THERAPEUTICS LTD·Filed 2020·Granted Jan 17, 2023·3 cites·14 claims
- 0390US10610578B2Checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapyIMMODULON THERAPEUTICS LTD·Filed 2018·Granted Apr 7, 2020·7 cites·16 claims
- 0487US10610577B2Checkpoint inhibitor and a whole cell Mycobacterium for use in cancer therapyIMMODULON THERAPEUTICS LTD·Filed 2014·Granted Apr 7, 2020·7 cites·13 claims
- 0587US2025170231A1Checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapyIMMODULON THERAPEUTICS LTD·Filed 2024·Application pending·0 cites
- 0685US8617520B2Cancer therapyAKLE CHARLES·Filed 2012·Granted Dec 31, 2013·9 cites·11 claims
- 0784US11000584B2Checkpoint inhibitor and a whole cell Mycobacterium for use in cancer therapyIMMODULON THERAPEUTICS LTD·Filed 2020·Granted May 11, 2021·1 cites·20 claims
- 0884US10994002B2Checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapyIMMODULON THERAPEUTICS LTD·Filed 2020·Granted May 4, 2021·1 cites·20 claims
- 0984US10925952B2Checkpoint inhibitor and a whole cell Mycobacterium for use in cancer therapyIMMODULON THERAPEUTICS LTD·Filed 2020·Granted Feb 23, 2021·1 cites·20 claims
- 1077US2023149525A1Immunogenic treatment of cancerIMMODULON THERAPEUTICS LTD·Filed 2023·Application pending·0 cites
- 1175US12042532B2Checkpoint inhibitor and a whole cell Mycobacterium for use in cancer therapyIMMODULON THERAPEUTICS LTD·Filed 2021·Granted Jul 23, 2024·0 cites·17 claims
- 1274US10071124B2Treatment of post-traumatic stress disorder with isolated MycobacteriumIMMODULON THERAPEUTICS LTD·Filed 2013·Granted Sep 11, 2018·2 cites·12 claims
- 1369US11207405B2Checkpoint inhibitor and a whole cell Mycobacterium for use in cancer therapyIMMODULON THERAPEUTICS LTD·Filed 2016·Granted Dec 28, 2021·1 cites·18 claims
- 1462US2022111046A1Checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapyIMMODULON THERAPEUTICS LTD·Filed 2021·Application pending·0 cites
- 1555US2014356397A1Immunogenic Treatment Of CancerIMMODULON THERAPEUTICS LTD·Filed 2012·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Charles Akle files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →